On-Demand Webinar
Animal component-free (ACF) cell culture media can improve consistency, safety, and regulatory compliance in CAR-T cell manufacturing. Attend this webinar for insights into how ACF media perform in both static and stirred systems, enabling more flexible and scalable manufacturing workflows for both autologous and allogeneic CAR-T therapies.
The effectiveness of two ACF media formulations will be evaluated in comparison to alternative ACF and xeno-free options, demonstrating how CAR-T cells cultured in ACF media maintained robust CAR expression over time, supporting long-term functionality. Additionally, the CAR-T cells demonstrated specific cytotoxicity against target cells, with a majority exhibiting a less differentiated phenotype, which is often associated with better persistence and efficacy in vivo.
Watch this webinar to gain an understanding in the shift towards animal-free, closed-system cell culture and how next-generation media solutions align with evolving standards in commercial CAR-T production.
What You Will Learn:
- Discover the limitations and potential safety concerns of using serum and other animal-derived supplements in T cell culture, and gain the knowledge and confidence to transition to ACF media
- Learn how ACF media can reduce safety and contamination risks and eliminate lot-to-lot variability, improving the safety and reproducibility of CAR-T cell products
- Gain insights on how to apply data-driven strategies to maintain robust CAR expression and promote less differentiated, functional T cells, improving therapeutic potential and persistence
- Explore how to achieve robust CAR expression and functional T cells for CAR-T cell manufacturing
